A mitoxyperiosis-associated redox-axis transcriptomic score stratifies prognosis and immune contexture in osteosarcoma A multi-cohort discovery and external-validation study

Abstract Background: Osteosarcoma is the most common primary malignant bone tumour in adolescents and young adults, and survival has plateaued for decades. Mitoxyperiosis is a recently described mechanism of mitochondria-dependent membrane lysis that links innate immune and metabolic signals to BAX/BAK1/BID-driven mitochondrial oxidation. Whether a compact transcriptomic proxy of the mitoxyperiosis redox axis carries prognostic and immunological information in osteosarcoma is unknown. Methods: We curated 205 osteosarcoma transcriptomes from four independent cohorts. TARGET-OS (n = 83) served as the discovery set; GSE21257, GSE39055 and GSE16091 (combined n = 122) served as the external validation set. A 39-gene mitoxyperiosis programme was reduced to a three-gene redox-axis signature (MRS = + 0.194·z(KEAP1) − 0.458·z(HMOX1) + 0.214·z(NOX4)) with weights derived in TARGET-OS and frozen before validation. We assessed discrimination, calibration, incremental value and proportional-hazards assumptions, and profiled the tumour microenvironment by ESTIMATE, ssGSEA and single-cell mapping. Results: In external validation, one standard-deviation increase in MRS was associated with an HR of 1.46 (95% CI 1.08–1.98, P = 0.015; I² = 0%). MRS-high tumours were immunologically cold, with lower T-cell-inflamed gene-expression activity (pooled ρ = −0.36), fewer cytotoxic lymphocytes and dampened antigen-presentation programmes. The NRF2-ARE target programme was suppressed in MRS-high samples. In single-cell data, lesion-level malignant MRS correlated negatively with T-cell-recruiting chemokines (ρ = −0.65) and NRF2 programming (ρ = −0.84). Conclusions: The MRS is a biologically interpretable, hypothesis-generating prognostic signature that captures an immune-excluded, oxidative-stress-rich osteosarcoma phenotype. It should not be used for clinical decision-making until independently validated in prospective cohorts.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-17
DOI
https://doi.org/10.21203/rs.3.rs-11351252/v1
Primary Topic
Sarcoma Diagnosis and Treatment
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

A mitoxyperiosis-associated redox-axis transcriptomic score stratifies prognosis and immune contexture in osteosarcoma A multi-cohort discovery and external-validation study

Dong Zhang, Yifan Wu, Huibao Hou, Yu Zhen
Research Square
Sarcoma Diagnosis and Treatment
preprint

A mitoxyperiosis-associated redox-axis transcriptomic score stratifies prognosis and immune contexture in osteosarcoma A multi-cohort discovery and external-validation study

Dong Zhang, Yifan Wu, Huibao Hou, Yu Zhen
preprint en

Abstract

Abstract Background: Osteosarcoma is the most common primary malignant bone tumour in adolescents and young adults, and survival has plateaued for decades. Mitoxyperiosis is a recently described mechanism of mitochondria-dependent membrane lysis that links innate immune and metabolic signals to BAX/BAK1/BID-driven mitochondrial oxidation. Whether a compact transcriptomic proxy of the mitoxyperiosis redox axis carries prognostic and immunological information in osteosarcoma is unknown. Methods: We curated 205 osteosarcoma transcriptomes from four independent cohorts. TARGET-OS (n = 83) served as the discovery set; GSE21257, GSE39055 and GSE16091 (combined n = 122) served as the external validation set. A 39-gene mitoxyperiosis programme was reduced to a three-gene redox-axis signature (MRS = + 0.194·z(KEAP1) − 0.458·z(HMOX1) + 0.214·z(NOX4)) with weights derived in TARGET-OS and frozen before validation. We assessed discrimination, calibration, incremental value and proportional-hazards assumptions, and profiled the tumour microenvironment by ESTIMATE, ssGSEA and single-cell mapping. Results: In external validation, one standard-deviation increase in MRS was associated with an HR of 1.46 (95% CI 1.08–1.98, P = 0.015; I² = 0%). MRS-high tumours were immunologically cold, with lower T-cell-inflamed gene-expression activity (pooled ρ = −0.36), fewer cytotoxic lymphocytes and dampened antigen-presentation programmes. The NRF2-ARE target programme was suppressed in MRS-high samples. In single-cell data, lesion-level malignant MRS correlated negatively with T-cell-recruiting chemokines (ρ = −0.65) and NRF2 programming (ρ = −0.84). Conclusions: The MRS is a biologically interpretable, hypothesis-generating prognostic signature that captures an immune-excluded, oxidative-stress-rich osteosarcoma phenotype. It should not be used for clinical decision-making until independently validated in prospective cohorts.

Research Square
Anhui Medical University (CN), Jiangsu Province Hospital (CN)
Anhui Medical University
Good health and well-being
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon